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ABSTRACT

AlAli Sally M.S. Department of Microbiology and Immunology, Wright State University,
2013. TLED Novel Approaches For The Eradication Of HIV Latently Infected Cells.

The development of a suitable experimental cell model to study HIV latency in primary
cells could have a massive effect on the current approaches to eradicate virus in latently
infected cells. The main proposal of this paper is to develop an in vitro HIV cell model
that represents HIV latency in vivo, then to create a more effective viral vector in order to
target HIV reservoirs. For this goal, a directed evolution method is suggested to be used
in order to mutate the AAV cap gene to generate a recombinant AAV vector that is
capable of infecting primary resting CD4+ T cells previously infected with HIV-1 and in
a latent stage.
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I.

INTRODUCTION

Human immunodeficiency virus (HIV) is a lentivirus in the Retroviridae family.
HIV causes acquired immunodeficiency syndrome (AIDS) in humans. Although the
development of highly active antiretroviral therapy (HAART) has increased life
expectancy, HIV reservoirs are still an obstacle to the eradication of the virus.
HIV latency is a big challenge scientists face to completely eliminate HIV from
patients’ bodies. In order to eradicate HIV latently infected cells, there is a big need to
understand the mechanism of HIV latency. One strategy is to prevent latency. Another
strategy for complete HIV eradication is to identify biomarkers for latently infected cells,
in order to target them in vivo. Targeting HIV reservoirs can be done either by antiretrovirus drugs, or gene therapy. Anti-retrovirus drugs could be a possible way for full
HIV eradication if it is specifically designed for eliminating HIV reservoirs. Gene
therapy is another targeting strategy; it is a promising approach for targeting latent
reservoirs.
The main challenge in understanding HIV latency is to have a paradigm that is
similar to in vivo latency. Studying HIV latency in vitro is an obstacle due to the lack of a
cell model that represents HIV latent reservoirs. The lack of cell model representing HIV
latency is behind the reason that latency establishment is possible to start in multiple
mechanisms. . A cell model representing HIV latency would allow the investigation of

1

these mechanisms. Moreover, HIV reservoirs are likely to be persistent in several cell
types (Bosque and Planelles, 2011).
Numerous efforts have been undertaken to create a novel cell model to study HIV
latency. Some of the early efforts to study latency have investigated chronically infected
cell lines such as JΔK (Antoni et al., 1994) and ACH2 (Jordan et al., 2003). JΔK cells
originated from the Jurkat T cell line. These cells are infected with HIV-1 virus, which
has deletion on its long terminal repeat (LTR) at the NFκB binding site. (Antoni et
al.,1994) these cells are different from primary cells because it is proliferating constantly.
Therefore, these cells never enter a quiescent stage. In the ACH2 cell model, tumor
necrosis factor – alpha (TNF-α) can reactivate the HIV latent virus (Jordan et al., 2003).
However, Tyagi, et al. (2010) reported no latent HIV-1 reactivation by TNF-α in a
primary CD4+ latently infected cell model.
Brooks, et al. (2001) generated an animal model by implanting a human fetal
thymus and liver tissues into severe-combined immunodeficient mice (Thy/Liv SCIDhu). This animal model is likely to be a promising alternative to in vitro research. The
model created by Brooks and colleagues allows the study of latency in naïve CD4+ T
cells, which contributes to 1.9% of HIV-1 reservoirs, while T central memory cells (TcM)
contribute with 51.7% and T transitional memory (TTM) gives about 34.3% (Chomont et
al., 2010).
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There have been several models developed that utilize primary T cells in order to
study latency. Primary T cells are permitted to enter latency after activation and infection
with HIV vectors. Several strategies have been used for this purpose such as, incubating
latently infected T cells with IL-7 (Marini et al. 2008), or taking advantage of CD4+ T
cells which can have an intermediate level of differentiation between two T cell subsets,
naïve T cells and effector T cells (Bosque and Planelles, 2011). This intermediate or un
committed phenotype will be referred to as non polarized CD4+ T cells in this paper.
Studies of HIV latency in previous cell models have given us deeper knowledge
about the possible mechanisms of latency. Understanding the mechanism of latency could
provide insights into promising approaches to prevent latency. However, there is a greater
possibility that latency may not be preventable from occurring. Therefore, targeting HIV1 reservoirs may be a more efficient way to achieve full eradication of HIV from the
body.
Identifying biomarkers for HIV reservoirs is an important step to target latently
infected cells. Several studies have reported that the majority of HIV reservoirs are TcM
and TTM subsets (Chomont et al., 2010), which both share the expression of CD45RO+
(Bosque and Planelles, 2011). Tyagi et al. (2010) identified HIV reservoirs, in the novel
-

+,

low

HIV latently infected cell model created by his team, as CD45RA , CD45RO CD27
CCR7

low

-

+

,

, CD25 , and CD38 . This finding is consistent with previous studies, which

suggest that TcM subsets represent HIV latently infected cells (Okada et al., 2008).
3

Several previous studies have used HIV-based vectors or replication deficient
HIV virus to infect CD4+ cells. In this paper, I propose to use wild type HIV to infect
primary restingCD4+ T cells in order to determine whether the latently infected cells will
express the same biomarkers reported in previous studies. The second objective in this
study will be to infect the HIV latently infected cells with an adeno-associated virus
(AAV), which will be created using a directed evolution technique, in order to originate a
novel therapeutic approach using gene therapy. This approach would be a more
promising and convenient method if combined with HAART regimen for full HIV
eradication.
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II.

BACKGROUND

The development of the high active antiretroviral therapy (HAART) has a huge
impact on controlling HIV infection, by acting on different phases of HIV life cycles.
This treatment has improved HIV patients’ life expectancy, by maintaining immune
system functions. It also protects patients from the opportunistic infections that frequently
cause death cases among acquired immunodeficiency syndrome (AIDS) patients.
Despite HAART improving the quality of life in HIV patients; therapy approaches have
not been able to eradicate HIV reservoirs. These reservoirs can persist in patient’s body
for approximately 44 months; these resting memory CD4+ T cells have low decay rates.
Thus, it takes about 60 years for full HIV eradication (Siciliano et al,. 2003).
HIV latently infected cells or HIV reservoirs are established early, during HIV
acute infection after initial infection. It is believed that memory T cells are the main
reservoir for HIV (Chomont et al., 2010). Moreover, Chomont et al. (2010) reported
TcM isolated from HIV-1 aviremic patients forms the majority of HIV-1 latently infected
cells. The same team also reported the presence of TTM subsets in the pool of HIV-1
reservoirs (Chomont et al., 2010).
HIV latently infected cells are in resting stage in vivo. Resting stage is identified
by the lack of cell activation markers, such as CD25, CD69, and HLADR (Bacchus et al.,
2013). HIV reservoirs are found in G0, which means decreased levels of cellular DNA
and RNA synthesis (Richman., 1980). The necessity of cells entering G0 to become HIV

5

latent cells has not been investigated. Another question with no answer is whether
transition from G0 to G1 phase is a crucial step for HIV reactivation.
There are three possible mechanisms for HIV latency in vivo. The first
mechanism suggests the return of an activated CD4+ T cell to the resting state after the
integration of HIV provirus. But for an activated, infected CD4+ T cell to survive, it must
escape activation-induced cell death because it eradicates the majority of activated cells.
Moreover, the cell must survive the HIV cytopathic effect (Shen et al., 2000).
Another possible theory for the establishment of HIV latency is that T cells allow
reverse transcription and integration. However, this reverse transcription is not sufficient
for viral replication. Infection through this time will allow the cell to avoid the HIV
cytopathic effect (Shen et al., 2000).
A third suggested mechanism for the establishment of HIV latency reported the
ability of resting CD4+ T cells to allow HIV integration and gene expression when these
cells are treated with cytokines such as IL-2, IL-7, IL-15 (Unutmaz et al., 1999).
These three hypotheses have not been investigated due to the difficulty in creating
an HIV latently infected cell model. It is hard to create a cell model that represents all cell
types that associate with HIV latency in vitro because multiple cell types are involved in
HIV latency in vivo. A second reason for the difficulty is that we still don’t know which
cytokine mechanism or pathway is significant in HIV reactivation in vivo (Yang et al.
2009). Last two decades have provided several studies aimed focused on understanding
the latency mechanism. Some of these studies investigate latency in chronically HIV6

infected cell lines (Antoni et al., 1993; Jordan et al., 2003), animal models (Brooks et al.,
2001), And primary cell culture (Tyagi et al,. 2010; Bosque and Planelles, 2011; Saleh et
al., 2010).
Jordan et al. (2003) created a latent HIV cell model using the ACH2 cell line.
This model is based on chronically infected T cells generated from the parental T cell
line, A3.01, that includes latent pro virus (Jordan et al., 2003). In this cell line Jordan and
colleagues reported that reactivation of HIV-1 from latency could occur after adding
TNF-α to the medium. However, the ACH2 cell line cannot represent true HIV latency
because this finding is different than Tyagi et al. who found no evidence of HIV-1
reactivation in HIV-1 latently infected cells in a primary isolated T cells upon TNF-α
treatment (Tyagi et al., 2010).
Another cell model based on a chronically infected cell line is the JΔK cell
model. In this model, cells are derived from the Jurkat cell line and chronically infected
with an HIV serotype that has a deletion in the long terminal repeat (LTR) at the NFκB
binding site (Antoni et al., 1993). In this model HIV-1 reactivation occurs in a fashion
independent of NFκB by incubating cells with PMA, hexamethylene bisacetamide or
sodium butyrate (Antoni, et al., 1993). More investigation is needed to know the effect of
the previous materials on any cell model that represents HIV latency in a more similar
way.
Antoni and Tyagi cell models gave us a deeper knowledge of a group of cytokines
that are associated with HIV-1 reactivation. However, the previous cell models are not
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completely parallel to the resting CD4+ T cells in G0 phase in HIV infected individuals
(Chun et al., 1997; Finzi et al., 1999)
Another different approach to create an HIV latently infected cell model was
originally created by Brooks et al. (2001). Using an animal model, Brooks and coworkers
developed an animal model using severe-combined immunodeficient mice that have an
implanted human fetal thymus (Brooks et al., 2001). Brooks and colleges generated
latency at a high rate during thymopoiesis. The vast majority of latent cells in this in vivo
model are naïve CD4+ T cells (Brooks et al., 2001). Naïve CD4+ T cells represents 1.9
% of HIV latently infected cells while TcM and TTM represent 51.7 and 34.3%
respectively (Chomont et al., 2009; OstrowskI. et al., 1999). Therefore, using this animal
cell model is promising for studying HIV latency in naïve CD4+ T cells. However, naïve
CD4+ T cells represent the minority in the population of HIV reservoirs.
Another possible strategy to create HIV latency cell model is the ex vivo culturing
of peripheral blood mononuclear cells (PBMC). By growing CD4+ T cells ex vivo, we are
generating a more parallel paradigm to HIV latency in vivo.

There are two main

challenges in using primary cells to create an ex vivo cell model for HIV latency. The
first challenge is the short half-life of the primary cells. These cells cannot survive more
than 20 days in vitro (Saleh et al., 2007; Peace et al., 2012). The second challenge is the
limited cell numbers obtained from these models (Peace et al., 2012; Bosque et al.,
2009). Several trials were established to obtain a cell model that represents HIV
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reservoirs in vivo using different strategies such as, non-polarized T cells (Bosque et al.,
2009), Bcl-2 cDNA transduced CD4+ T cells (Yang et al., 2009), and activated T cells
co-cultured with a feeder cell line (Tyagi et al., 2010).
Bosque and coworkers (2009) took advantage of non-polarized cells since they
can be activated to Th1 and Th2 T cells or stay inactivated as TcM. The cells were
infected with an env deficient HIV (DHIV), then cultured with medium that included IL2 (Bosque et al,. 2009). Although this cell model generated a large number of latently
infected cells with different subtypes, cell viability was 20% at the end of the resting
stage (Bosque et al., 2009). An important advantage of this model is the convenience of
drug screening that could target various steps of HIV latency. However, this model is not
perfect for studying HIV that targets chemokine receptor (R5 tropic virus) since these
cells express lower CCR5 levels due to the activation step.
Yang et al. (2009) transduced primary cells with lentiviral vector that expressed
the B cell lymphoma-2 gene (BCL-2), which encodes an anti-apoptotic protein located
downstream of IL-7 signaling (Yang, et al., 2009). Therefore, Inhibition of apoptosis
allowed cells to survive longer independent of cytokine stimulation. This model
generated enough cells, which is optimal for drug screening. However, the majority of
model cells developed by Yang et al. (2009) generated effector memory T cells. These
cells are the second minority after naïve T cells in HIV reservoirs pool (Chomont, et al.
2009). Moreover, mutated HIV vector could potentially affect the results because it does
not represent HIV wild type accurately.
9

Tyagi and colleagues (2010) infected activated primary CD4+ T cells isolated
from healthy donors. After activation and infection with mutated HIV vector, cells were
co-cultured with an H80 feeder cell line (Sahu et al,. 2006; Tyagi et al., 2010). This cell
model overcame the problem of the short half-life of latent cell models ex vivo (Sahu et
al., 2006; Tyagi et al., 2010). Also, this cell model showed that epigenetic silencing and
restricted P-TEFb levels contribute to HIV latency (Tyagi, et al., 2010). However, coculturing activated CD4+ T cells with the H80 feeder cell line results in a comparatively
homogenous population of TcM (Tyagi et al., 2010). This means that the Tyagi and
colleagues (2010) cell model does not allow the study of other T cell subsets that
contribute to HIV latent cells pool such as the TTM subset (Chomont, et al., 2009).
Furthermore, cells in nature are not completely resting as it appears in Tyagi and
coworkers’ cell model, CD25

high

high

and Ki67

which means that these cells are actively

proliferating (Tyagi et al., 2010). Finally, the use of mutated HIV may affect the behavior
of the latent virus.
The latent cell models discussed previously used activated T cells (Bosque et al.,
2009; Yang et al., 2009; Sahu et al., 2006: Tyagi et al., 2010), using activated T cells in
HIV latent cell models can produce a large number of cells, which is suitable for drug
screening (Bosque et al., 2009; Yang et al., 2009). However, activated T cells in a latent
model result in a homogenous population of one T cell subset, such as a TcM population,
resulted after activated T cells were co-cultured for a long period of time with H80 feeder
10

cells (Sahu et al., 2006; Tyagi et al., 2010). Thus, using activated T cells, as an HIV
latent cell model does not parallel HIV latency in vivo. There is a big need to study HIV
latency in a cell model that represents HIV reservoirs in vivo. The more similar the model
is to in vivo HIV latency the greater benefit we get in identifying reservoirs and the
biomarkers on these cells. Identifying biomarkers of HIV reservoirs is a promising
strategy in targeting these cells to full HIV eradication.
The using of resting T cells in creating an HIV latent cell model could represent
in vivo HIV latency in a more precise way. Direct infection of primary resting CD4+ T
cells prevents any stimulation or activation that could change cellular characteristics, thus
we can obtain CD4+ T cells potentially as they exist in the body. It is predicted that using
resting cells will give us more accurate results, and it will allow us to study latency in all
T cell types. Peace and colleagues (2012) developed an HIV latent cell model using
resting T cells. In this cell model resting cells were spinoculated with HIV WT to
increase infection. This experiment was done to measure the integration, transcription,
and translation of HIV proteins; it shows that resting CD4+ cells have the ability to
produce HIV Gag protein without enhancing the spread of infection (Peace et al., 2012).
This study reflects the latency features of HIV in vivo. Also, it can give us more accurate
results for T cells biomarkers as they are in the body. However, T cells in the Peace and
coworkers cell model do not survive for longer than 20 days in vitro (Peace et al., 2012).
This is considered a disadvantage in studying HIV latent cells, particularly when studying
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HIV latency for drug screening or gene therapy.
Identifying biomarkers for HIV reservoirs is necessary to develop strategies to
target these cells efficiently. Several studies identified biomarkers for HIV latent cells in
primary CD4+ T cell (Tyagi et al., 2010; Bosque et al., 2009). These two studies revealed
-

+

similar features of latently infected CD4+ T cells, which are CD45RA , CD45RO ,
CCR7

+

, CD27+. These cell markers show that HIV latent cells have the central memory

T cells phenotype (Tyagi et al., 2010; Bosque et al., 2009). Additionally, Tyagi and
colleagues investigated the cell proliferative state by detecting the nuclear proliferation
markers Ki67 and BrdU in HIV latently infected cells in the cell model (Tyagi et al.,
2010). The results show that the majority but not all latent cells are quiescent. Tyagi and
coworkers suggest that the Ki67 positive cells are viable for a longer time when treated
with IL-2 (Tyagi et al., 2010). However, both Tyagi and Bosque previous studies were
done in cell models that were not quite parallel to in vivo HIV latency since Tyagi’s
model resulted in a homogenous T cells subset of T central memory cells (Tyagi et al.,
2010), and the Bosque cell model had a majority of non-polar T cells that express
+

CD45RA (Bosque et al., 2009). On the other hand, Bacchus and colleagues identified
biomarkers for HIV reservoir in vivo, which were CD25-, CD69-, and HLADR- (Bacchus
et al. 2013). Additionally, this study revealed four resting CD4+ T cells subsets that
contribute to the different percentages of subsets found in the in vivo HIV latency pool.
These four resting CD4+ T cells subsets are: naive (CD45RA+CCR7+CD27+) 2%,
12

central-memory (CD45RA-CCR7+CD27+) 17%, transitional memory (CD45RA-CCR7CD27+) 58%, and effector memory cells (CD45RA-CCR7-CD27-) 9.7% (Bacchus et al.,
2013). Comparing HIV latent cells isolated as described in the method section below to
these studies described above using the same biomarkers will allow us to compare the
similarity of our cell model to the in vivo HIV latent cell populations.
Pace et al. (2012) developed a cell model that revealed an important feature of
HIV reservoirs, which is the Gag protein persistence in these cells. Resting T cells
produce a smaller quantity of HIV proteins and fewer types of HIV proteins (Pace et al.,
2012). Results found by Pace and coworkers are consistent with the in vivo results that
the Gag protein is more predominant in resting cells than env and vif proteins (Zhang et
al., 1999). Thus, targeting HIV reservoirs producing Gag protein will be more beneficial
than targeting latent HIV cells expressing env (Berger, and Pastan, 2010)
In this paper I propose to use primary resting CD4+ T cells without activation,
then to infect these cells with HIV WT in order to have the advantage of a parallel cell
model to HIV latency in vivo. Thus, identifying cell markers before and after infection
will be more efficient to determine the changing that occurs in T cells subsets and
phenotypes before and after infection. Another purpose of this system is to target HIV
latent cells with adeno-associated virus (AAV). Targeting cells needs HIV latent cells to
survive for long period. Thus, cells will be co-cultured with H80 feeder cell line to ensure
cell survival in our cell model.
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Gene therapy is a potential method to cure several diseases. It has shown
encouraging results in treating diseases such as cystic fibrosis (Wagner JA, et al.
1998; Excoffon et al., 2009), improvement of vision in Leber congenital amaurosis
patients (Maguire et al. 2008), and severe combined immunodeficiency SCID-X1
disease (Cavazzana et al., 2000). With using gene therapy, scientists can deliver a
gene in order to correct a defective gene in patient’s body, or to improve cell
capability to fight infectious agents. Thus, it can be said that gene therapy is a
developed form of drug delivery, and it could be applied for a vaccination strategy.
AAV is a member of of the Parvoviridae family and is a Dependovirus.
The AAV wild type genome is 4.7 Kb, it is a linear, single stranded DNA virus
with 2 open reading frames ORFs. The first open reading frame is rep, this area
encodes transcripts for 4 proteins that are required for AAV genome replication.
The second ORF is cap and encodes 3 proteins (VP1-3) that build the AAV
capsid (Muzyczka , Berns , 2001). AAV is a potential viral vector candidate that
may target HIV reservoirs for several reasons; first, AAV capsid is highly
evolved; this capsid could be engineered in a way that it can change AAV tropism
since it is encoded by a single gene (Summerford , Samulski ,1998; Walters , et
al., 2001; Gao et al. 2004). Mutating the AAV cap is a possible strategy to target
cells other than those that AAV WT usually infects. The second reason that makes
AAV a better viral vector is the high level of safety when using this virus in
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humans. AAV has never been documented to cause human disease (Moss et al.,
2007). Also, the ability of AAV Type 2 to infect lymphocytes was investigated in
3 B cell subsets and 4 T cell types; the results show that AAV is able to infect all
tested lymphocyte subsets (Mendelson et al., 1992). Moreover, AAV has been
reported to successfully infect alveolar cells, which are mature, non-dividing cells
(Mendelson et al., 1992). Finally, the development of synthetic biology
techniques such as, directed evolution would be promising if it is used with AAV
to create a mutated cap gene, which can change AAV tropism and target more cell
types in a more efficient and specific fashion.
Inouye and coworkers reported a strong inhibition of HIV-1 in primary T
cells and alveolar macrophages when they delivered combined anti-Rev singlechain immunoglobulin (SFv) or Rev response element (RRE) decoy genes
delivered by AAV vector (Inouye, et al.,1997). It is also a promising strategy to
create a vaccine that prevents HIV infection. Furthermore, it shows that immune
cells (T cells and alveolar macrophages) are capable of being infected with more
than one virus, AAV and Ad5 and HIV (Inouye, et al., 1997). However, the
efficient delivery of this strategy has not been yet investigated.
Mendelson et al.(1992) reported an increase of about 60-70% in HIV-1
reverse transcription when lymphocytes are co-infected with either adenovirus or
adeno-associated virus alone (Mendelson et al., 1992). The increase of reverse
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transcription activity was decreased by about 20% when cells were infected with
AAV plus Ad2 virus together (Mendelson et al., 1992). The study highlights an
important advantage of AAV, which is the ability of these viruses to interact with
HIV-1 after infecting lymphocytes. Thus, T cells can survive after being infected
with 3 viruses (Mendelson et al., 1992). However, the yield of infectious AAV
was low in most cases (Mendelson et al., 1992). The low rate of infectious AAV
could be due to the low viral tropism to lymphocytes. Therefore, developing AAV
cap gene for better infection of lymphocytes using directed evolution would be a
possible way to target HIV reservoirs in our HIV latent cell model.
The directed evolution strategy has a potential effect in changing the
functional properties of enzymes, proteins, and genes. Directed evolution occurs
when we applied selective pressure to a library of objects in order to get the most
desired properties of these objects.
Excoffon et al. (2009) demonstrated the capability of AAV to develop
remarkably greater infectivity within the airway epithelium when a library of
AAV cap mutants were placed under selective pressure. When the AAV vector
was customized with the mutated AAV cap gene after directed evolution, it was
better able to infect human airway epithelia (Excoffon et al., 2009). Thus, using
directed evolution to mutate AAV cap gene in order to infect HIV latent cells is
likely a promising approach in targeting HIV reservoirs.
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The first goal in this paper is to generate an efficient HIV latency model
that is parallel to the in vivo HIV latency pool. Our HIV latent cell model will
allow us to identify HIV latent cells’ biomarkers before and after being infected
with HIV WT. To guarantee that cells will survive for longer time, cells will be
co-cultured with the H80 feeder cell line (Sahu et al., 2006; Tyagi et al., 2010).
Additionally, our novel cell model will give us the chance to investigate the
reasons behind the predominant levels of HIV Gag protein in latently infected
cells reported by Pace and colleagues (Pace et al., 2012). The second goal of this
study is to engineer a viral vector that is capable of infecting HIV reservoirs and
express a GFP gene or an anti-HIV gene within these latent cells. AAV is a
potential candidate for targeting HIV reservoirs due to its high safety profile in
humans. Targeting HIV latent cells with AAV vector that is capable to get high
gene expression could be a significant step towards the eradication of HIV
reservoirs in patients’ body.

17

III.

AN OVERVIEW OF THE METHOD

T cell isolation:
T cells will be isolated from PBMC. To purify resting T cells, we can stain
the cells with R-Phycoerythrin (PE) Conjugated Antibodies against CD25, CD69,
and HLA-DR, and then use Anti-PE magnetic beads (Pace et al., 2012). Pace and
colleagues method in isolating resting CD4+ T cells has a purity greater than 98%
(Pace et al., 2012).
Purified cells can go through more investigation to identify resting CD4+
T cells biomarkers, and compare the obtained subtypes with the in vivo studies by
Bacchus et al. (2013) The four resting CD4+ T cells subsets in this study are:
naive (CD45RA+CCR7+CD27+) 2%, central-memory (CD45RA-CCR7+CD27+)
17%, transitional memory (CD45RA-CCR7-CD27+) 58%, and effector memory
cells (CD45RA-CCR7-CD27-) 9.7% (Bacchus et al., 2013)
Incubating resting CD4+ T cells:
Resting CD4+ T cells will left in RPMI medium, containing 10% fetal calf
serum (FCS) and antibiotics, with no stimulation (Pace et al., 2012).
Other resting CD4+ T cell groups will be stimulated with either IL-7 or
anti-CD28/CD3. Stimulated CD4+ T cells will used to evaluate the differences
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between cell markers in resting CD4+ T cell with/without stimulation, and then
compare our results with the in vivo results by Bacchus et al. (2013).
Stimulated and non-stimulated resting CD4+ groups will be tested for the
following biomarkers: CD45RA, CD45RO, CCR7, CD27, CD25, CD69.
Identifying CD4+ T cells biomarkers will be helpful to determine the difference in
T cell subsets in each CD4+ T cells groups (stimulated/ non-stimulated).
Infecting CD4+ T cells:
Stimulated and non-stimulated CD4+ T cells will be infected with HIV WT. Cells
will be stained with trypan blue stain to ensure cell viability.
One of the big concerns in this stage is that HIV WT could induce cell death.
Therefore, using Drug resistant HIV variants is likely to be a good alternative strategy if
HIV WT caused cell death. Another pitfall in our HIV latent cell paradigm is the spread
of HIV in cell culture. Therefore, cell media will include antiretroviral drug to select for
cells with HIV integration but not replication.
Identifying Biomarkers for CD4+ T cells post infection:
Same cell biomarkers in Bacchus et al. (2013) study will be identified which are:
naive

(CD45RA+CCR7+CD27+),

central-memory

(CD45RA-CCR7+CD27+)

,

transitional memory (CD45RA-CCR7-CD27+) , and effector memory cells (CD45RA-
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CCR7-CD27-) (Bacchus et al. 2013). in order to determine CD4+ T cells subsets after
entering latency. Moreover, Ki67 and BrdU staining will be performed to check the
proliferation stage of the cells.
For further investigations, chromatin immunoprecipitation (ChIP) assay will be
performed as described in Tyagi et al. (2007). ChIP assay will be performed in order to
determine the levels of chromatin in resting primary CD4+ models.
Long-term incubation:
Cells will be incubated for long period using the H80 feeder cell line as
previously described in the Tyagi and coworkers paradigm (Tyagi et al., 2010).
Pitfall: HIV WT could infect H80 feeder cells. Thus, using H80 feeder cells
supernatants may be a possible way to maintain HIV latent cells if our model cells
survive, and to avoid an HIV cytopathic effect on H80 feeder cells if it occurs.
AAV viral vector construction:
AAV viral vector will be constructed using the directed evolution method as
previously described by Excoffon et. al (2009). Briefly, AAV2 and AAV5 cap genes will
be amplified via PCR. DNA shuffling will be performed as previously described (Zaho
et al., 1998; Stemmer, 1994). Next, the chimeric cap genes will be cloned in pSub2 for
recombinant AAV (rAAV) construction (Maheshri et al., 2006). Error-prone PCR will be
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done for subsequent evolution sequences (Maheshri et al., 2006).
The method for viral production will be as previously described by Excoffon and
colleagues (Excoffon et al,. 2009).
rAAV in vitro selection and characterization :
To select the best AAV vector that is able to infect HIV latent cells, AAV will be
diluted in EMEM and added to HIV latent cells. After 16 hours of incubation,
unbound viruses will be washed off with PBS (Excoffon et al., 2009). Three days
later, AAV vectors will be amplified by adding Ad5 as a helper virus, as previously
described (Maheshri et al., 2006). After 3 days, AAV DNA will be recovered by PCR
amplification and cloned into pSub2 to produce more rcAAV, and selected for pXX2
NotI for rAAV production (Koerber et al., 2008).
To determine the relative efficiency of AAV transduction in HIV latent cells, the
latter will be infected with rAAV vectors that carry cDNA encoding green fluorescent
protein (GFP). The percentage of GFP cells will be quantified using flow cytometry
48 hours post infection (Excoffon et al., 2009). Cells will be stained with Trypan blue
to check viability.
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